182 related articles for article (PubMed ID: 31148330)
1. No evidence of association between psychological distress and pain relief in patients with bone metastases from castration-resistant prostate cancer treated with 223Radium.
De Vincentis G; Frantellizzi V; Follacchio GA; Farcomeni A; Pani A; Samaritani R; Schinzari G; Santini D; Cortesi E
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13112. PubMed ID: 31148330
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy.
van der Doelen MJ; Oving IM; Wyndaele DNJ; van Basten JP; Terheggen F; van de Luijtgaarden ACM; Oyen WJG; van Schelven WD; van den Berkmortel F; Mehra N; Janssen MJR; Prins JB; Gerritsen WR; Custers JAE; van Oort IM
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):142-150. PubMed ID: 35804188
[TBL] [Abstract][Full Text] [Related]
3. Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC.
Frantellizzi V; Lazri J; Pontico M; Pani A; De Vincentis G
Arch Ital Urol Androl; 2020 Oct; 92(3):. PubMed ID: 33016042
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
[TBL] [Abstract][Full Text] [Related]
5. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Basch EM; Scholz M; de Bono JS; Vogelzang N; de Souza P; Marx G; Vaishampayan U; George S; Schwarz JK; Antonarakis ES; O'Sullivan JM; Kalebasty AR; Chi KN; Dreicer R; Hutson TE; Dueck AC; Bennett AV; Dayan E; Mangeshkar M; Holland J; Weitzman AL; Scher HI
Eur Urol; 2019 Jun; 75(6):929-937. PubMed ID: 30528222
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
Zhang I; Gilbo P; Kohn N; Cox B
Pract Radiat Oncol; 2018; 8(6):452-457. PubMed ID: 29934137
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
Küronya Z; Sinkovics I; Ágoston P; Bíró K; Bodrogi I; Böde I; Dank M; Gyergyay F; Vajdics T; Kolonics Z; Nagyiványi K; Rúzsa Á; Géczi L
Pathol Oncol Res; 2017 Oct; 23(4):777-783. PubMed ID: 28074331
[TBL] [Abstract][Full Text] [Related]
9. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
11. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
12. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
Frantellizzi V; Farcomeni A; Follacchio GA; Pacilio M; Pellegrini R; Pani R; De Vincentis G
Ann Nucl Med; 2018 Feb; 32(2):142-148. PubMed ID: 29285670
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer.
Wilson JM; Parker C
Expert Rev Anticancer Ther; 2016 Sep; 16(9):911-8. PubMed ID: 27501059
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
15. A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
Myint ZW; El Khouli R; Lemieux B; Yan D; St Clair WH; Liu X; Kunos CA
BMC Cancer; 2022 Apr; 22(1):415. PubMed ID: 35428207
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
Serretta V; Valerio MR; Costa R; Tripoli V; Murabito A; Princiotta A; Scalici Gesolfo C; Borsellino N; Verderame F; Gebbia V; Licari M; Sanfilippo C;
Urol Oncol; 2019 Dec; 37(12):964-969. PubMed ID: 31601517
[TBL] [Abstract][Full Text] [Related]
17. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
19. Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.
Vogelzang NJ
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):809-819. PubMed ID: 28649893
[TBL] [Abstract][Full Text] [Related]
20. Screening for psychological distress before radiotherapy for painful bone metastases may be useful to identify patients with high levels of distress.
Westhoff PG; de Graeff A; Monninkhof EM; Berveling MJ; van Vulpen M; Leer JWH; Marijnen CAM; Reyners AKL; van der Linden YM;
Acta Oncol; 2017 Dec; 56(12):1720-1727. PubMed ID: 28893119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
